Protara Therapeutics, Inc. (TARA)
TARA moved a median of 0.00% 30 minutes after news, and -0.47% by the close. How TARA actually reacts to news — the realized, point-in-time move the market made, measured across 275 labeled events over the last three years with zero look-ahead.
TARA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 272 |
| 30-min | 0.00% | 46% | 274 |
| 60-min | -0.52% | 45% | 274 |
| to close | -0.47% | 41% | 274 |
| Middle 50% of TARA reactions | -1.91% to +1.55% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 275 |
Half of all Protara Therapeutics, Inc. news events land between -1.91% and +1.55% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TARA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 18 | +1.61% | 67% | +0.27% |
| Rating reiterations | 35 | 0.00% | 46% | +0.69% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how TARA ranks against every other measured name →
That’s how TARA usually reacts — get an email when it moves on news →Email me when TARA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TARA's baseline. Nothing else.
Recent TARA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support | Press release | GlobeNewswire | -0.37% | -4.38% | |
| Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.65% | -0.78% | |
| Form 10-Q Protara Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.25% | -2.25% | |
| Form 8-K Protara Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | -2.25% | |
| Form S-8 Protara Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.25% | -2.75% | |
| Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update | Press release | GlobeNewswire | -1.25% | -2.25% | |
| Form 8-K Protara Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -3.99% | -4.74% | |
| Form 8-K Protara Therapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | -3.54% | |
| Form EFFECT Protara Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.80% | -4.00% | |
| Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | Press release | GlobeNewswire | +3.17% | +7.94% | |
| Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 | Press release | GlobeNewswire | -0.39% | -9.80% | |
| Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC | Press release | GlobeNewswire | +0.56% | -0.58% | |
| Form S-3 Protara Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.10% | +1.73% | |
| Form 10-Q Protara Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.77% | -1.89% | |
| Form 8-K Protara Therapeutics, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -3.77% | -1.89% | |
| Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update | Press release | GlobeNewswire | -3.77% | -1.89% | |
| Form ARS Protara Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.99% | +2.17% | |
| Form DEF 14A Protara Therapeutics, For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | +0.99% | +2.17% | |
| Form DEFA14A Protara Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.99% | +2.17% | |
| Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting | Press release | GlobeNewswire | +3.59% | +1.00% | |
| Form PRE 14A Protara Therapeutics, For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | -0.37% | -1.67% | |
| Form 8-K Protara Therapeutics, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.62% | |
| Form 10-K Protara Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -2.73% | |
| Form 8-K Protara Therapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.73% | |
| Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | Press release | GlobeNewswire | +0.00% | -2.73% | |
| Form 8-K Protara Therapeutics, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -2.24% | -12.48% | |
| TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | Press release | GlobeNewswire | -2.24% | -12.48% | |
| Protara Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.53% | +7.68% | |
| Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.56% | -5.06% | |
| Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium | Press release | GlobeNewswire | +1.73% | +2.25% | |
| Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones | Press release | GlobeNewswire | -3.55% | -9.34% | |
| Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support | Press release | GlobeNewswire | -0.19% | +6.96% | |
| Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.19% | +6.96% | |
| Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations | Press release | GlobeNewswire | -0.35% | -4.60% | |
| Form 8-K Protara Therapeutics, For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | -1.27% | |
| Form 8-K Protara Therapeutics, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -0.49% | +1.24% | |
| Protara Announces Closing of $75 Million Public Offering | Press release | GlobeNewswire | -0.49% | +1.24% | |
| Protara Announces Pricing of $75 Million Public Offering | Press release | GlobeNewswire | -1.50% | +4.30% | |
| Protara Announces Proposed Public Offering | Press release | GlobeNewswire | -1.50% | +4.30% | |
| Form 8-K Protara Therapeutics, For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +1.19% | |
| Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients | Press release | GlobeNewswire | -0.89% | +1.19% | |
| Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 | Press release | GlobeNewswire | -2.93% | -8.80% | |
| Form 8-K Protara Therapeutics, For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -5.88% | +5.17% | |
| Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations | Press release | GlobeNewswire | -5.88% | +5.17% | |
| Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 | Press release | GlobeNewswire | -5.88% | +5.17% | |
| Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology | Press release | GlobeNewswire | -0.36% | +1.46% | |
| Form 10-Q Protara Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.82% | +5.84% | |
| Form 8-K Protara Therapeutics, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | +5.84% | |
| Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.82% | +5.84% | |
| Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace | Press release | GlobeNewswire | +0.00% | -4.92% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TARA section they belong to.
Where else TARA is measured.
TARA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Protara Therapeutics, Inc.'s median reaction calculated?
Every labeled TARA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 275 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of TARA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TARA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.